We are live on ! Find out more
KLRS

Kalaris Therapeutics
KLRS

Fund managers haven’t disclosed any holdings of KLRS yet.

KLRS Hedge Fund Activity: Q1 2026 in Review

58 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Kalaris Therapeutics (KLRS) for Q1 2026, worth a combined $107M — down 29% from $152M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new KLRS positions and 7 closed out — a net gain of 8 holders — while 16 added to existing stakes and 7 trimmed.

The largest buyer was Propel Bio Management, adding an estimated $2.25M. The largest seller was Redmile Group, exiting entirely with an estimated $700K sold.

  • 58 institutional investors held Kalaris Therapeutics (KLRS) as of Q1 2026, up from 51 in Q4 2025.
  • Funds reported $107M of Kalaris Therapeutics stock for Q1 2026, down 29% quarter-over-quarter.
  • 15 funds opened new Kalaris Therapeutics positions in Q1 2026 and 7 closed out, a net change of +8 holders.
  • The largest Kalaris Therapeutics buyer in Q1 2026 was Propel Bio Management, an estimated $2.25M added.
  • The largest Kalaris Therapeutics seller in Q1 2026 was Redmile Group, an estimated $700K sold.

Based on aggregated 13F filings for Q1 2026.